|
Source
|
Title
|
|
Journal of Controlled Release 72 (2001) 191–202
|
In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
|
|
Clinical Cancer Research Vol. 10, 3708–3716, June 1, 2004
|
Phase I and Pharmacokinetic Study of Genexol®-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies
|
|
Breast Cancer Res Treat (2008) 108:241–250
|
Multicenter phase II trial of Genexol®-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
|
|
Annals of Oncology 18: 2009–2014, 2007
|
Multicenter phase II trial of Genexol®-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
|
|
Annals of Oncology 21: 382–388, 2010
|
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
|
|
Cancers 2011, 3, 17-42;
|
Clinically Relevant Anticancer Polymer Paclitaxel Therapeutics
|
|
Cancer Investigation, 28:186–194, 2010
|
Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer
|
|
Cancer Chemother Pharmacol (2014) 74:277–282
|
A phase II trial of Cremorphor EL‑free paclitaxel (Genexol®‑PM) and gemcitabine in patients with advanced non‑small cell lung cancer
|
|
Int J Radiation Oncol Biol Phys, Vol. 86, No. 3, pp. 463e468, 2013
|
Preclinical Evaluation of Genexol®-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer
|
|
Invest New Drugs (2012) 30:1984–1990
|
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
|
|
EJSO 36 (2010) Abstract No. 456
|
Determination of maximum-tolerated dose (MTD) of Genexol®-PM (GPM), estimation of efficacy and safety of GPM in aggregate with Gemcitabine treatment in patients with advanced pancreatic cancer
|
|
J Breast Cacner 2010 March; 13(1): 104-10
|
Cost-effectiveness of Genexol®-PM for treating metastatic breast cancer
|
|
2014 San Antonio Breast Cancer Symposium Abstract No. P3-10-04
|
A open-label, randomized, parallel, phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® (conventional paclitaxel with cremorphor EL) in recurrent or metastatic breast cancer patients
|
|
Clinical Lung Cancer, Vol. 14, No. 3, 275-82
|
Paclitaxel-Loaded Polymeric Micelle (230 mg/m2) and Cisplatin (60 mg/m2) vs. Paclitaxel (175 mg/m2) and Cisplatin (60 mg/m2) in Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase IIB Trial
|
|
Cancer Res April 15, 2013 73; 4659 / AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC
|
Phase Ⅱ study of a weekly liposomal paclitaxel formulation (Genexol®-PM) and gemcitabine combination chemotherapy in patients with advanced biliary cancer
|
J Thorac Oncol. 2015
Dec;10(12):1800-6.
|
A Prospective Phase Ⅱ Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol®-PM) in Patients with Unresectable Thymic Epithelial Tumors.
|
|
J Clin Oncol 31, 2013 (suppl; abstr 5568)
|
An open label, randomized, parallel, phase Ⅱ trial to evaluate the efficacy and safety of cremophor-free, polymeric micelle formulation of paclitaxel compared to paclitaxel in subjects with ovarian cancer.
|
|
Journal of Gynecologic Oncology, 2017 Mar; 28(2):e26
|
An open-label, multicenter, phase I trial of a cremophor-free, polymeric micelle formulation of paclitaxel combined with carboplatin as a first-line treatment for advanced ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3016)
|
|
The Korean Cancer Association (Manuscript ID: CRT-16-376, 2017)
|
An open-label, randomized, parallel, phase II trial to evaluate the efficacy and safety of a cremophor-free polymeric micelle formulation of paclitaxel as first-line treatment for ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG-3021)
|
|
ASCO 2017 (Abstract Number for Publication: 1082)
|
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495)
|
|
IIT ongoing study
|
A phase II study of Genexol®-PM and cisplatin as induction chemotherapy in unresectable, locally advanced head and neck squamous cell carcinoma (HNSCC)
|
|
A phase II trial of Doxorubicin and Genexol®-PM in patients with advanced breast cancer
|
|
Dose-dense paclitaxel (Genexol®-PM) once a week in combination with carboplatin every 3 weeks for gynecologic cancer (adult solid tumor): a phase I trial
|
|
Phase Ⅱ Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects with Recurrent and Metastatic Adenocarcinoma of the Pancreas
|
|
A Phase II Study of Weekly Genexol®-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
|
